QRL-101, an oral small molecule being developed by QurAlis, was safe and reduced nerve-cell overactivity in ALS patients in ...

To request an in-person meeting with Gain management on Wednesday during the week of the J.P. Morgan Healthcare Conference, either register at LifeSci Partners Corporate Access Event 2026 or contact ...

Shares of Alumis Inc. (NASDAQ:ALMS) were selling for $16.93, up $8.62, or 103%, having traded as high as $22.30 on positive top-line results from the phase III Onward1 and Onward2 trials with ...

Some kids' braina are literally wired to process food differently, and they need specific support, not just more time.

See some of the top-viewed videos from Trevor Ottmann on job-site tips, tricks, and experiences that we published on ...

SynuSight Biotech has licensed (18) F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment ...

MG added a glut of new products last year but sales went backwards. Now, it's getting a pair of new executives to head up local operations.

Follow live updates as developments emerge on Venezuela's future and U.S. allies respond to Trump's threats against Greenland ...

Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS exposures in the projected therapeutic range, and target engagement with ...

SynuSight Biotech has licensed 18 F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment . SHANGH ...

As India prepares for the Union Budget 2026 on February 1, the insurance industry has outlined a broad set of expectations ...

The two approved vehicle models need to operate under strictly confined parameters. The Changan model is limited to ...